Vignesh Packiam, MD

This account is verified. Learn more

@VigneshPackiam

Associate Prof @RutgersCancer @rwjurology | Previously at @UIowa_Urology | Alum @MayoClinic @Uro_Onc, @UChicagoUro, @PittMedAlum, @UWBadgers| Views my own

New Jersey cinj.org/vignesh-t-pack… Joined November 2013

1.4K Following 1.7K Followers 1.8K Posts

Latest posts 5

Vignesh Packiam, MD @VigneshPackiam 3d

One of my fav recent studies… great TUR makes big impact

UroToday.com Verified account @urotoday 4d

JCOG1019 Trial: Active Surveillance Versus BCG for T1 Bladder Cancer with Negative Second TUR.
Can BCG be skipped in high-grade T1 #BladderCancer after a negative second TUR? @hiroshi_dko
joins @UroDocAsh to discuss JCOG1019: surveillance was non-inferior to BCG. #WatchNow > bit.ly/3TGTm6S

View quoted post on X

Vignesh Packiam, MD @VigneshPackiam 3d

Double bonus:
- Enrolled another patient onto the SUMMIT trial! Treating HG UTUC with kidney sparing approach clinicaltrials.gov/study/NCT06822…
- They gave a reading list as a gift.. seems perfect as Abraham Verghese is great (Covenant of Water)

Vignesh Packiam, MD @VigneshPackiam Oct 28

Nice article and history @MatveyTsivian Cutaneous U is a nice option in some and underutilized. Have used in patients w crohns, extensive prior small bowel surgery, or very frail. Single stoma is nice, can Wallace at skin or do a wide TUU. Works especially well if patient skinny +\- hydro @RyanWerntzMD @patelsg1 @SBoorjian

MUSC Urologic Oncology Program Verified account @MUSC_UroOnc Oct 27

🚨 What is the role of cutaneous ureterostomy after radical cystectomy?

@RayAMC48 @LuisMedinaMD @MatveyTsivian and team explore the contemporary role of single-stoma cutaneous ureterostomy as a urinary diversion option in the urinary diversion armamentarium.

🔗 mdpi.com/1718-7729/33/8…

@EMW2000 @MatveyTsivian @SES_AUA @UroOnc @SUO_YUO @LuisMedinaMD @RayAMC48

View quoted post on X

Vignesh Packiam, MD @VigneshPackiam Oct 24

Still not worth it IMO

Difference in recurrence is low and those can be salvaged with regimens providing much less toxicity

Julian Chavarriaga @chavarriagaj Oct 24

#ESMO26 A subgroup analysis of the phase III POTOMAC trial in papillary-only high-risk NMIBC:

📌Papillary-only: DFS HR 0.56; 48-month DFS 84% vs 74%
📌T1 subgroup: DFS HR 0.48; 48-month DFS 85% vs 73%
📌High-risk recurrence: 13% vs 20% in papillary-only disease
📌 Fewer early high-risk events, BCG-unresponsive recurrences and cystectomies
📌The trade-off: Grade 3–4 AEs were 34% vs 16%.
@UroToday @myESMO

View quoted post on X

Vignesh Packiam, MD @VigneshPackiam Oct 24

Yes sometimes this is nice!

@RyanWerntzMD

Trushar Patel Verified account @TrusharPatelMD Oct 24

🤖 I love robotic surgery—but not every case needs a robot🔪

Modified Makuuchi incision can be a safe, efficient option for complex urologic oncology cases.

✅ Massive tumors (>18 cm)
✅ Complex IVC thrombus (Levels I–IV)
✅ T4 disease
✅ Adrenocortical carcinoma
✅ Complex anatomy

👉 Haven’t tried a Makuuchi incision? Consider it for better upper intrabdominal exposure.

📖 doi.org/10.7759/cureus…
View quoted post on X